News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,170 Results
Type
Article (8017)
Company Profile (140)
Press Release (476916)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166768)
Career Advice (306)
Deals (25740)
Drug Delivery (7)
Drug Development (52879)
Employer Resources (14)
FDA (9761)
Job Trends (8577)
News (238246)
Policy (17931)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33155)
ALS (105)
Alzheimer's disease (980)
Antibody-drug conjugate (ADC) (272)
Approvals (10390)
Artificial intelligence (323)
ASCO (159)
Autoimmune disease (208)
Automation (28)
Bankruptcy (263)
Best Places to Work (6958)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (112)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (29)
Breast cancer (515)
Cancer (3686)
Cardiovascular disease (221)
Career advice (245)
Career pathing (1)
CAR-T (175)
CDMO (7)
Celiac Disease (1)
Cell therapy (479)
Cervical cancer (34)
Clinical research (47925)
Collaboration (1253)
Commercialization (3)
Compensation (1477)
Complete response letters (34)
COVID-19 (757)
CRISPR (64)
C-suite (761)
Cystic fibrosis (85)
Data (5721)
Denatured (4)
Depression (102)
Dermatology (63)
Diabetes (345)
Diagnostics (4194)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (156)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73733)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87758)
Executive appointments (706)
FDA (12426)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (929)
Gene editing (126)
Generative AI (9)
Gene therapy (324)
GLP-1 (291)
Government (946)
Grass and pollen (2)
Guidances (281)
Healthcare (9331)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (59)
Indications (157)
Infectious disease (945)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (258)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (11)
Liver cancer (45)
Longevity (18)
Lung cancer (514)
Lymphoma (254)
Machine learning (27)
Management (3)
Manufacturing (540)
Marketing (8)
MASH (118)
Medical device (8664)
Medtech (8812)
Mergers & acquisitions (14392)
Metabolic disorders (710)
mRNA (59)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (40)
Neuroscience (1836)
NextGen: Class of 2026 (3150)
Non-profit (842)
Obesity (225)
Opinion (10)
Ovarian cancer (160)
Pain (173)
Pancreatic cancer (201)
Parkinson's disease (201)
Partnered (12)
Patents (482)
Patient recruitment (514)
Peanut (31)
People (41266)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15476)
Phase 2 (21399)
Phase 3 (14429)
Pipeline (7457)
Policy (18)
Postmarket research (1570)
Preclinical (6542)
Press Release (34)
Prostate cancer (191)
Psychedelics (7)
Radiopharmaceuticals (191)
Rare diseases (577)
Real estate (3020)
Recruiting (6)
Regulatory (14868)
Reports (21)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (157)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (331)
Venture capital (17)
Weight loss (73)
Women's health (82)
Date
Today (117)
Last 7 days (315)
Last 30 days (1600)
Last 365 days (19035)
2026 (12710)
2025 (19251)
2024 (22988)
2023 (26538)
2022 (34592)
2021 (37167)
2020 (33469)
2019 (23256)
2018 (17494)
2017 (18765)
2016 (17921)
2015 (24268)
2014 (21679)
2013 (18135)
2012 (20222)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (74)
Alaska (2)
Arizona (306)
Arkansas (11)
Asia (17921)
Australia (2102)
California (12081)
Canada (3177)
China (530)
Colorado (488)
Connecticut (414)
Delaware (208)
Europe (24650)
Florida (1811)
Georgia (386)
Hawaii (3)
Idaho (46)
Illinois (708)
India (51)
Indiana (317)
Iowa (15)
Japan (412)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1208)
Massachusetts (7917)
Michigan (308)
Minnesota (564)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (118)
New Hampshire (60)
New Jersey (2642)
New Mexico (12)
New York (2837)
North Carolina (1293)
North Dakota (4)
Northern California (6066)
Ohio (282)
Oklahoma (14)
Oregon (16)
Pennsylvania (2269)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5015)
Tennessee (122)
Texas (1965)
United States (39209)
Utah (363)
Vermont (1)
Virginia (154)
Washington D.C. (38)
Washington State (935)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,170 Results for "flugen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone
July 12, 2024
·
5 min read
BioMidwest
FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference
FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced Boyd Clarke, Executive Chairman is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference.
January 5, 2022
·
1 min read
BioMidwest
FluGen to Present at Baird’s 2021 Global Healthcare Conference
FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced management is scheduled to present at the Baird 2021 Global Healthcare Conference on Tuesday, September 14 at 5:30 PM E.T.
September 7, 2021
·
1 min read
BioMidwest
New Data Published in the Journal of Infectious Diseases Demonstrate FluGen’s M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains
FluGen, Inc. today announced the publication of new data in the Journal of Infectious Diseases showing its investigational, high dose, intranasal H3N2 M2SR influenza vaccine candidate substantially enhanced mucosal and serum antibodies against drifted H3N2 influenza viruses.
November 9, 2022
·
4 min read
BioMidwest
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
FluGen, Inc., today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old.
September 7, 2022
·
4 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Press Releases
Glucotrack, Inc. Announces Reverse Stock Split
August 27, 2026
·
6 min read
Business
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu.
April 2, 2020
·
4 min read
Drug Development
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company’s investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.
August 2, 2021
·
5 min read
Press Releases
argenx Completes Acquisition of Forte Biosciences, Inc.
August 27, 2026
·
6 min read
1 of 48,517
Next
